3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
Conditions
Tourette Syndrome
1
Stress Disorders, Post-Traumatic
1
Sleep Initiation and Maintenance Disorders
1
Severe Acute Respiratory Syndrome
1
Seizures
1
Parkinson Disease
1
Opioid-Related Disorders
1
Neoplasms
1
Multiple Sclerosis
1
Inflammatory Bowel Diseases
1
Hepatitis C
1
Glaucoma
1
Fibromyalgia
1
Epilepsy
1
Depression
1
Crohn Disease
1
Coronavirus Infections
1
Colitis, Ulcerative
1
Chronic Traumatic Encephalopathy
1
Chronic Pain
1
COVID-19
1
Brain Injuries, Traumatic
1
Bipolar Disorder
1
Autistic Disorder
1
Anxiety Disorders
1
Anemia, Sickle Cell
1
Amyotrophic Lateral Sclerosis
1
Acquired Immunodeficiency Syndrome
1
Interventions
fludarabine phosphate
2
fludarabine
2
Whole-Body Irradiation
2
Tacrolimus
2
Surveys and Questionnaires
2
Proton Therapy
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Music Therapy
2
Mesna
2
Melphalan
2
Interviews as Topic
2
Gene Expression Profiling
2
Cyclophosphamide
2
Busulfan
2
tremelimumab
1
motesanib diphosphate
1
luprolide acetate gel depot
1
liposomal amphotericin B
1
durvalumab
1
copanlisib
1
chlorhexidine gluconate
1
batifiban
1
Whole Genome Sequencing
1
Watchful Waiting
1
Thrombopoietin
1
Taxes
1
Spermine Synthase
1
Radiotherapy, Intensity-Modulated
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NETWORK
×
Neoplasms
×
Medical Marijuana
×
Clear all
NCT03944447
2022-06-02
OMNI-Can
OMNI Medical Services, LLC
Phase 2
Unknown
200,000 enrolled